• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Scottish Health Technologies Group (SHTG) Minuteful Kidney for home testing of albumin-to-creatine ratio (ACR)
2022     NIHR Health Technology Assessment programme Improving the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography (Perfusion CT)
2022     Scottish Health Technologies Group (SHTG) Chest wall bracing for children and young people with pectus carinatum
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022     NIHR Health Technology Assessment programme Enhancing social-emotional health and wellbeing in the early years: a community-based randomised controlled trial (and economic) evaluation of the Incredible Years Infant and Toddler (0-2) Parenting Programmes
2022     NIHR Health Technology Assessment programme Development and evaluation of machine learning methods in whole body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer (MAchine Learning In whole Body Oncology, MALIBO)
2022     NIHR Health Technology Assessment programme Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022     Agency for Care Effectiveness (ACE) Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022     NIHR Health Technology Assessment programme FEMME trial: Randomised trial of treating Fibroids with either Embolisation or MyoMectomy to measure the Effect on quality of life
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022     Agency for Care Effectiveness (ACE) Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022     NIHR Health Technology Assessment programme A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)
2022     Agency for Care Effectiveness (ACE) The PrecivityAD test for the prognosis of Alzheimer's disease
2022     NIHR Health Technology Assessment programme Fast-Forward: a randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in women with early breast cancer
2022     Basque Office for Health Technology Assessment (OSTEBA) [Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2022     Agency for Care Effectiveness (ACE) Artificial intelligence and its clinical applications
2022     Basque Office for Health Technology Assessment (OSTEBA) [Image-guided spinal fusion technology]
2022     Agency for Care Effectiveness (ACE) 3D printing and its clinical applications
2022     Basque Office for Health Technology Assessment (OSTEBA) [Temporary percutaneous circulatory support devices for the treatment and prevention of cardiogenic shock: analysis of efficacy, effectiveness and safety]
2022     Agency for Care Effectiveness (ACE) Overview of clinical applications of telemedicine
2022     Agency for Care Effectiveness (ACE) Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: amyotrophic lateral sclerosis with or without frontotemporal dementia NGS panel]
2022     NIHR Health Technology Assessment programme Gastric Bypass, adjustable gastric Banding or Sleeve gastrectomy surgery to treat severe and complex obesity: a multi-centre randomised controlled trial (The By-Band-Sleeve Study)
2022     NIHR Health Technology Assessment programme POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes
2022     Agency for Care Effectiveness (ACE) Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022     NIHR Health Technology Assessment programme The PRmotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with prediabetes (PROPELS): randomised controlled trial in a diverse multi-ethnic community
2022     NIHR Health Technology Assessment programme E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022     Agency for Care Effectiveness (ACE) Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022     NIHR Health Technology Assessment programme Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2022     NIHR Health Technology Assessment programme RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022     NIHR Health Technology Assessment programme Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodules
2022     Center for Evidence-based Practice (CEP) VTE chemoprophylaxis for patients undergoing elective spinal surgery
2022     Center for Evidence-based Practice (CEP) Video camera-assisted or electromagnetic placement of enteral feeding tubes
2022     NIHR Health Technology Assessment programme Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial (HEAT)
2022     Center for Evidence-based Practice (CEP) Pneumocystis jirovecii pneumonia (PJP) prophylaxis
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022     NIHR Health Technology Assessment programme Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022     Health Sciences Institute in Aragon (IACS) Efficacy, safety and efficiency of sentinel lymph node magnetic localisation techniques in breast cancer
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2022     WorkSafeBC Dry needling for lateral elbow pain
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2022     WorkSafeBC Efficacy and/or effectiveness of treatments for lateral epicondylitis - barbotage and ultrasonic tenotomy
2022     WorkSafeBC Fat grafting for nerve padding
2022     WorkSafeBC Intravenous ketamine for PTSD and treatment-resistant depression
2022     Medical Services Advisory Committee (MSAC) Genetic testing for childhood hearing impairment
2022     NIHR Health Technology Assessment programme The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) The role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department with suspected or confirmed Acute Coronary Syndrome
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2022     WorkSafeBC Sweat lodge usage as treatment for depression or other psychological disorders
2022     Medical Services Advisory Committee (MSAC) Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer disease
2022     Norwegian Institute of Public Health (NIPH) Surgical procedures for treatment of obesity: health technology assessment
2022     NIHR Health Technology Assessment programme Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)
2022     Center for Evidence-based Practice (CEP) Organizational strategies to improve or promote healthcare worker wellness
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2022     Norwegian Institute of Public Health (NIPH) Screening for preeclampsia with use of an algorithm - protocol for full HTA - project description
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 2 - overview of liver transplantation in Québec]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease
2022     NIHR Health Technology Assessment programme VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot. The VIOLET Study
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: somatic variant classification and stratification strategies]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: next generation sequencing hereditary cancer gene panels]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Solriamfetol (obstructive sleep apnoea) - Benefit assessment according to ?35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Liaison Psychiatry: Measurement And Evaluation of Service Types, Referral patterns and Outcomes LP-MAESTRO
2022     NIHR Health Technology Assessment programme Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial
2022     NIHR Health Technology Assessment programme Comparison of ALitretinoin with PUVA as the first line treatment in patients with severe chronic HAnd eczema (ALPHA trial)
2022     NIHR Health Technology Assessment programme Early detection of neovascular age-related macular degeneration
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     NIHR Health Technology Assessment programme Intravenous immunoglobulin in the management of encephalitis in children
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albutrepenonacog alfa (haemophilia B) - Assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Catheter Ablation versus thoracoscopic Surgical Ablation in long standing persistent Atrial Fibrillation (CASA-AF)
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to adolescents)
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (Peanut allergy) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery for the treatment of patients with brain metastases]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (sleep apnoea) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A21-101]
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stent retriever for the treatment of cerebral artery vasospasm after subarachnoid haemorrhage]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2022     NIHR Health Technology Assessment programme The effectiveness of adjunctive medication management and contingency management to enhance adherence to medications for relapse prevention in alcohol dependence
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Cerclage Suture Type for an Insufficient Cervix and its effect on Health outcomes (C-STICH)
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK (ARRISA-UK): a pragmatic cluster randomised trial with nested economic and process evaluations examining the effects of integrating at-risk asthma registers into primary care with internet-based training and support
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): A randomised, double-masked, sham- controlled, clinical trial comparing low-voltage X-ray irradiation with as needed ranibizumab, to as needed ranibizumab monotherapy
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational exposure and upper extremity pain]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for total knee replacement]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Delamanid (pulmonary multi-drug resistant tuberculosis, body weight >= 10 kg) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Food in diabetes]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cefiderocol (infections) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V]